Delaware SUPPORT Office Based Opioid Treatment (OBOT) Fellowship - Clinical Provider Track
Delaware has the second highest rate of drug overdose in the country; of those overdose deaths, 88% involved opioids. Further, in Delaware, 61 opioid prescriptions are written for every 100 residents. Delaware also ranks first in the country for high-dose and long acting-opioid prescriptions, both of which increase the risk of OUD and overdose. One of the most effective interventions to reduce opioid related mortality is the delivery of evidence-based treatment including medication for opioid use disorder. Like most states, Delaware does not have sufficient treatment capacity for opioid use disorder. Because there are too few addiction medicine specialists, it is critical that primary care, women's health, and infectious disease specialists who are seeing patients in the community increase their confidence and training to be able to identify and treat opioid use disorder. A variety of barriers have been identified as contributors to buprenorphine underutilization including: insufficient training, education and experience; lack of institutional and clinician peer support; poor care coordination; provider stigma; inadequate or burdensome reimbursement; and burdensome regulatory procedures. Increasing office based opioid treatment (OBOT) in Delaware will lead to an increase in access to opioid use disorder treatment. Delaware Medicaid has received a grant from the Center for Medicare and Medicaid Services to improve addiction treatment capacity.
The OBOT Fellowship clinical track is designed to educate clinicians on identification, diagnosis and treatment of opioid use disorder. Additionally, time will be spent working to reduce stigma against people who use drugs and to help clinicians increase their level of comfort in talking about drug use and working with people who use drugs. We are utilizing self-paced courses as the first component. In addition, the webinars that will be provided over the 6 month period are designed to foster a Delaware based learning collaborative. Specifically, the topics covered during self-paced modules will include: Introduction to Working with People Who Use Drugs, Addiction, and medications for opioid use disorder (MOUD); Intake Assessment and Buprenorphine Initiation; Follow-Up Visit Management and Prevention of Recurrence; Engaging Patients in Their Care; Toxicology Interpretation; Overdose Prevention Strategies; Stigma and Harm Reduction; Opioid Use Disorder and Mental Health Illnesses; Maternal Care and Opioid Use Disorder; Opioid Use Disorder and Peripartum Management; Opioid Use Disorder and HIV/HCV; and Using Telemedicine for Linkage and Continuity in OUD Treatment during the Coronavirus Pandemic.
This activity is designed for clinicians.
Elements of Competence
This CE activity has been designed to improve learner competence and performance and focuses on the American Board of Medical Specialties' areas of patient care and procedural skills and medical knowledge.
This activity focuses on the Interprofessional competencies of roles/responsibilities, interprofessional communication, and teams/teamwork.
This activity also focuses on the Institute of Medicine competencies of provide patient-centered care; work in interdisciplinary teams and employ evidence-based practice.
At the conclusion of the activity, the administrative healthcare team members will be able to:
- Describe the evidence base of medications for opioid use disorder treatment.
- List three ways medical providers can reduce stigma against people who use drugs.
- Explain how harm reduction principles can be applied in the delivery of office-based opioid treatment.
1.1 Introduction to medications for opioid use disorder (MOUD)
1.2 Stigma and harm reduction
1.3 Overdose prevention
1.4 Synchronous Discussion
2.1 Intake assessment and buprenorphine initiation
2.2 Engaging patients in care
2.3 Using telemedicine
2.4 Synchronous Discussion
3.1 Follow-up management and relapse prevention
3.2 Toxicology interpretation
3.3 OUD and mental health illness
3.4 Synchronous Discussion
4.2 Managed care
4.3 Peripartum management
4.4 Synchronous Discussion
*The 6 months of Technical Assistance (TA) will occur from April-September 2021.
This is a virtual conference (eastern time). Please see the Program for further information.
A link will be sent to participants prior to the activity start date.
Clinical Director/Planning Committee Chair(s):
Krishna Winfrey, BS, Principal Researcher
Maliha Ali, MBBS, DrPH, Researcher
Quy Nhi Cap, MPH, Researcher
Daniel Harwell, MS, Researcher
Sarah Mossburg, BSN, MS, PhD, Researcher
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM
Mishka Terplan, MD MPH FACOG DFASAM
Claire Viscione, BS, Research Assistant
Additional Committee Members:
Anika Alvanzo, MD, Physician
Amanda Brooks, LCSW CADC, Licensed Clinical Social Worker and Certified Alcohol and Drug Counselor
Kathryn Basques, MSW MSN, APN, PMHMP-BC, Nurse Practitioner
Megan Buresh, MD, Physician
Nicole Michele Gastala, MD, Physician
Terry Horton, MD, FACP, DABAM, Physician
POLICY ON DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests* in order to allow CE staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).
For this educational activity, all conflicts of interest have been resolved and detailed disclosures are listed below:
Financial Relationship Disclosures
Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation?
|Maliha Ali, MBBS, DrPH||Committee Member||No relevant financial relationships to disclose||No|
|Anika Alvanzo, MD||Speaker/Author||American Society of Addiction Medicine (Fiduciary Officer), Maryland Department of Health and Mental Hygiene (Contractor); Pyramid Healthcare, Inc. (Employment)||No|
|Terese Bailey, BS||Planner||No relevant financial relationships to disclose||No|
|Kathryn Basques, MSW, MSN, APN, PMHMP-BC||Speaker/Author||No relevant financial relationships to disclose||Yes|
|Amanda Brooks, LCSW, CADC||Speaker/Author||No relevant financial relationships to disclose||No|
|Megan Buresh, MD||Speaker/Author||American Society of Addiction Medicine (Contractor)||No|
|Quy Nhi Cap, MPH||Committee Member & Planner||No relevant financial relationships to disclose||No|
|Nicole Gastala, MD||Speaker/Author||No relevant financial relationships to disclose||No|
|Daniel Harwell, MS||Committee Member||No relevant financial relationships to disclose||No|
|Terry Horton, MD, FACP, DABAM||Speaker/Author||Masimo (Consultant and Advisory Group Member)||No|
|Sarah Mossburg, BSN, MS, PhD||Committee Member||No relevant financial relationships to disclose||No|
|Elizabeth Salsbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM||Committee Member, Speaker/Author, Content Reviewer||No relevant financial relationships to disclose||No|
|Mishka Terplan, MD, MPH, FACOG, DFASAM||Committee Member, Speaker/Author, Content Reviewer||No relevant financial relationships to disclose||No|
|Claire Viscione, BS||Committee Member||No relevant financial relationships to disclose||No|
|Krishna Winfrey, BS||Committee Member||No relevant financial relationships to disclose||No|
*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
|In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and the American Institutes for Research (AIR). The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.|
Credit Designation Statements
American Medical Association (AMA)
The University of Wisconsin–Madison ICEP designates this blended (enduring/live) activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
The University of Wisconsin–Madison ICEP designates this blended (enduring/live) activity for a maximum of 11.75 ANCC contact hours.
Continuing Education Units (CEUs)
The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 1.175 continuing education units (CEUs) or 11.75 hours.
Jointly Provided by:
The American Institutes for Research (AIR)
University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)
- 11.75 AMA PRA Category 1 Credit™
- 11.75 ANCC Contact Hours
- 11.75 University of Wisconsin–Madison Continuing Education Hours
- 11.75 Approved for AMA PRA Category 1 Credit™
Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Internet Explorer could produce error messages or not display the content correctly. Free, current version of Adobe Acrobat Reader or other .pdf reader